Sugi Predict

Sugi Predict / Compounds / SCHEMBL14979003

SCHEMBL14979003

SCHEMBL14979003

Cc1cc2n(n1)COc1ccccc1-2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MME P08473 1/20 0.40
▸ KDM4E B2RXH2 9/20 0.39
▸ HSD17B10 Q99714 8/20 0.39
▸ ALDH1A1 P00352 6/20 0.39
▸ HPGD P15428 5/20 0.39
▸ GAA P10253 3/20 0.39
▸ NPC1 O15118 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ HTT P42858 2/20 0.35
▸ ALOX15 P16050 1/20 0.35
▸ MAPT P10636 4/20 0.34
▸ MAPK1 P28482 2/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ PKM P14618 2/20 0.33
▸ TSHR P16473 1/20 0.33
▸ ADORA3 P0DMS8 1/20 0.33
▸ DRD1 P21728 1/20 0.33
▸ SLC5A7 Q9GZV3 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14979000 0.84 KDM4E (0.38) MMEKDM4EHSD17B10ALDH1A1HPGD
SCHEMBL14979001 0.82 MME (0.43) MMEKDM4EHSD17B10ALDH1A1HPGD
SCHEMBL18409004 0.81 MME (0.41) MMEALDH1A1GAAMAPTPKM
SCHEMBL9963886 0.80 MME (0.38) MMEPKMTSHRADORA3DRD1
SCHEMBL9966410 0.80 MME (0.40) MMEMEN1KMT2APKMTSHR
SCHEMBL15474173 0.79 MME (0.46) MMEKDM4EHSD17B10ALDH1A1HPGD
SCHEMBL14978999 0.79 MME (0.46) MMEKDM4EHSD17B10ALDH1A1HPGD
SCHEMBL15474172 0.79 MME (0.46) MMEKDM4EHSD17B10ALDH1A1HPGD
SCHEMBL20066495 0.76 MME (0.38) MMENPC1RAB9AMAPTMAPK1
SCHEMBL14126188 0.73 GABRG2 (0.39) MMEKDM4EALDH1A1GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10759813-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2020-09-01 — — US disclosed
US-20200031847-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2020-01-30 — — US disclosed
US-9845332-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2017-12-19 — — US disclosed
US-20170320895-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2017-11-09 — — US disclosed
US-9771337-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2017-09-26 — — US disclosed
US-9724359-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2017-08-08 — — US disclosed
US-9725448-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2017-08-08 — — US disclosed
US-20170217959-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2017-08-03 — — US disclosed
US-9688692-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2017-06-27 — — US disclosed
US-20170088526-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2017-03-30 — — US disclosed
US-20150133658-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2015-05-14 — — US disclosed
US-20140364603-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2014-12-11 — — US disclosed
US-8853427-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2014-10-07 — — US disclosed
US-8846913-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2014-09-30 — — US disclosed
US-20140046053-A1 NEPRILYSIN INHIBITORS THERAVANCE, INC. (US) 2014-02-13 — — US disclosed
US-20140011997-A1 NEPRILYSIN INHIBITORS THERAVANCE, INC. (US) 2014-01-09 — — US disclosed
US-8563512-B2 Neprilysin inhibitors THERAVANCE, INC. (US) 2013-10-22 — — US disclosed
US-20130245260-A1 NEPRILYSIN INHIBITORS THERAVANCE, INC. (US) 2013-09-19 — — US disclosed
US-8481044-B2 Neprilysin inhibitors THERAVANCE, INC. (US) 2013-07-09 — — US disclosed
US-8449890-B2 Neprilysin inhibitors THERAVANCE, INC. (US) 2013-05-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140011997-A1 NEPRILYSIN INHIBITORS MME, REN, ACE MME 1/4885KDM4E 2334/4885HSD17B10 3448/4885
US-10759813-B2 Neprilysin inhibitors MME, REN, ACE MME 1/4885KDM4E 2334/4885HSD17B10 3448/4885
US-20150133658-A1 NEPRILYSIN INHIBITORS MME, REN, EDNRB MME 1/4885KDM4E 2255/4885HSD17B10 3555/4885
US-20170320895-A1 NEPRILYSIN INHIBITORS MME, REN, ACE MME 1/4885KDM4E 2334/4885HSD17B10 3448/4885
US-20200031847-A1 NEPRILYSIN INHIBITORS MME, REN, ACE MME 1/4885KDM4E 2334/4885HSD17B10 3448/4885
US-20140046053-A1 NEPRILYSIN INHIBITORS MME, REN, ACE MME 1/4885KDM4E 2334/4885HSD17B10 3448/4885
US-20170217959-A1 NEPRILYSIN INHIBITORS MME, REN, ACE MME 1/4885KDM4E 2334/4885HSD17B10 3448/4885
US-20170088526-A1 NEPRILYSIN INHIBITORS MME, REN, ACE MME 1/4885KDM4E 1855/4885HSD17B10 3947/4885
US-20140364603-A1 NEPRILYSIN INHIBITORS MME, REN, ACE MME 1/4885KDM4E 1928/4885HSD17B10 3820/4885
US-20130245260-A1 NEPRILYSIN INHIBITORS MME, REN, EDNRB MME 1/4885KDM4E 2255/4885HSD17B10 3555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.